A5051986152- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- T-cell and B-cell Immunology
- Platelet Disorders and Treatments
- MicroRNA in disease regulation
- Animal Virus Infections Studies
- Herpesvirus Infections and Treatments
- Genetics, Aging, and Longevity in Model Organisms
- vaccines and immunoinformatics approaches
- Multiple Myeloma Research and Treatments
- Radiopharmaceutical Chemistry and Applications
- Circular RNAs in diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Reproductive System and Pregnancy
- Rheumatoid Arthritis Research and Therapies
- Cytomegalovirus and herpesvirus research
- Blood groups and transfusion
- Protein purification and stability
- Nanofabrication and Lithography Techniques
- Hemoglobinopathies and Related Disorders
Servier (France)
2025
Fred Hutch Cancer Center
2020-2024
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa
2023
Takeda (United States)
2021-2022
Cancer Research Center
2022
University Hospital of Basel
2015-2019
University of Basel
2013-2015
Friedrich Miescher Institute
2013-2015
The skin at the site of HSV-2 reactivation is enriched for HSV-2–specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory cells, we studied biopsies and HSV-2–reactive CD4+ cells from PBMCs by cell receptor (TCR) β chain (TRB) sequencing before after vaccination with a replication-incompetent whole-virus candidate (HSV529). representation TRB sequences in repertoire increased first dose. We found sustained expansion unique, clonotypes that were not...
Abstract Background: Conditional 4-1BB activation has emerged as an attractive approach to overcome the hepatoxicity or suboptimal efficacy associated with agonistic mAbs. PRS-344/S095012 is a tetravalent PD-L1/4-1BB bispecific molecule designed simultaneously inhibit PD-1/PD-L1 signaling and provide PD-L1-dependent activation—offering promising dual mechanism enhance antitumor immunity while reducing related toxicity. Preclinical data demonstrated trimerization robust (Peper-Gabriel et al.,...
Abstract Background: Activation of the 4-1BB co-receptor can enhance anti-tumor immune responses but has historically resulted in excessive toxicity. PRS-344/S0905012 is a “2+2” tetravalent, bispecific antibody-Anticalin fusion protein (Mabcalin), designed to activate PD-L1-dependent manner. In preclinical studies PRS-344/S095012 showed superior efficacy compared monospecific anti-PD-L1 or antibodies. Methods: We tested phase 1, first-in-human study (NCT05159388) patients (≥18 years) with...
Objectives: To explore long-term effects of treatment and prognostic relevance variables assessed at baseline during the European secondary progressive multiple sclerosis (SPMS) trial interferon beta 1b (IFNB-1b). Methods: We 362 patients (60% female; median age 41 years; Expanded Disability Status Scale (EDSS): 5.5; 51% randomized to IFNB-1b) for their EDSS history after 10 years. Non-parametric analysis covariance (ANCOVA) multivariate linear regression models were applied. Results: Median...
Almost three years into the SARS-CoV-2 pandemic, hybrid immunity is highly prevalent worldwide and more protective than vaccination or prior infection alone. Given emerging resistance of variant strains to neutralizing antibodies (nAb), it likely that T cells contribute this protection. To understand how sequential mRNA-vectored spike (S) vaccines affect cell clonotype-level expansion kinetics, we identified cross-referenced TCR sequences from thousands S-reactive single against deeply...
ABSTRACT The skin at the site of HSV-2 reactivation is enriched for HSV-2-specific T cells. To evaluate whether an immunotherapeutic vaccine could elicit skin-based memory cells, we studied biopsies and HSV-2-reactive CD4 + cells from peripheral blood mononuclear (PBMCs) by cell receptor β ( TRB ) sequencing before after vaccination with a replication-incompetent whole virus candidate (HSV529). representation sequences PBMCs in repertoire increased first dose. We found sustained expansion...
<h3>Background</h3> Conditionally activated bispecific T cell engagers (TCEs) have the potential to provide a larger therapeutic window by reducing off-site on-target toxicity. Bispecific Redirected Activation (COBRAs) are novel TCEs designed be preferentially in tumor microenvironment (TME).<sup>1,2</sup> The conditionality of COBRA prodrug is mediated upon binding high affinity target domain antigen and cleavage matrix metalloproteases such as MMP9/2. results release inactive CD3e VH/VL...
<h3>Background</h3> T Cell Receptor (TCR)-T cell therapies have shown some promising results in cancer clinical trials, however the efficacy of treatment remains suboptimal. Outcomes could potentially be improved by utilizing highly functional TCRs for future trials. Current TCR discovery methods are relatively low throughput and rely on synthesis screening individual based tetramer binding peptide specificity, which is costly labor intensive. We developed validated a pooled approach relying...